Lilly may extend grant disclosure policy globally

Share this article:
Eli Lilly said it is studying the feasibility of extending its grants disclosure policy globally and could do so by next year.

Publishing the data on worldwide education grants and charitable contributions would complement the Indianapolis drug firm's decision last May to publicize grants given to US organizations. Lilly posts the information on its educational grants portal on a quarterly basis.

Lilly CEO Sidney Taurel said the firm is “working hard to evaluate the legal, regulatory and other considerations” related to disclosing the information worldwide, targeting 2008 as a possible timeframe.

He made the statement in a letter to the group Essential Action, which is leading a broad coalition of public health and consumer organizations leaning on Big Pharma to disclose all of its charitable and educational grants and gifts. Arguing that such funding influences physician prescribing, the coalition said disclosure “doesn't cure this problem, but it is a start.”

So far, the only company set to follow Lilly onto the grant disclosure bandwagon is Pfizer. In April its Medical Education Policy Committee recommended the adoption of a policy on disclosure of educational grants. The company will begin reporting grants given to US organizations in 2008.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.